Lipella Pharmaceuticals has launched an Oral Lichen Planus, or OLP, patient registry. This online platform is designed to enhance research and drive the development of new treatments for OLP, a chronic inflammatory disease affecting the mucous membranes of the mouth.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LIPO:
- Lipella Pharmaceuticals Launches Innovative Registry to Advance Oral Lichen Planus Research
- Lipella Pharmaceuticals Unveils Advanced Bladder Imaging Technique at ICICJ Conference
- Lipella Pharmaceuticals Doses First Two Patients in Phase 2a Oral Lichen Planus Clinical Trial
- Lipella Pharmaceuticals doses first two patients with LP-310
- Biotech Alert: Searches spiking for these stocks today